마이크로플루이딕스 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the microfluidics market size is projected to be USD 24.15 billion in 2025, USD 26.90 billion in 2026, and reach USD 46.13 billion by 2031, growing at a CAGR of 11.39% from 2026 to 2031.

This report is Segmented by Product Type (Microfluidic-Based Devices, Microfluidic Components [Microfluidic Chips, and More]), Application (Drug Delivery, Point-Of-Care Diagnostics, and More), Material (Polymer, Silicone, and More), Technology (Continuous-Flow Microfluidics, and More), End-User (Diagnostic Laboratories, and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

Global Microfluidics Market Trends and Insights

Increasing Demand for Point-of-Care Testing

Healthcare providers value rapid diagnostic answers that guide real-time therapeutic choices, cut emergency room congestion, and prevent repeat admissions. Microfluidic lateral-flow cartridges paired with optical readers deliver quantitative biomarker results in under 15 minutes, exemplified by the SepTec sepsis test that flags bloodstream infections at clinically relevant concentrations. During 2024-2025 the U.S. FDA granted 23 Emergency Use Authorizations for microfluidic COVID-19 assays, cementing an accelerated review precedent manufacturers now leverage for chronic disease tests. Reimbursement policy also aligns; Medicare's ADLT framework offers favorable payment when assays demonstrate clinical utility, prompting hospitals to replace manual workflows with automated, closed microfluidic systems. The effect is immediate: demand for single-use cartridges that integrate extraction, amplification, and detection grows swiftly, especially in urgent-care clinics where skilled lab personnel are scarce. As supply chains stabilize, manufacturers focus on expanding test menus covering cardiac, metabolic, and respiratory panels, reinforcing the momentum of the microfluidics market.

Rising Incidences of Chronic and Infectious Diseases

A growing global burden of diabetes, cardiovascular disorders, and chronic kidney disease fuels continuous monitoring solutions that eliminate repeated venipuncture. Microfluidic sensors analyzing interstitial fluid or saliva suit pediatric and geriatric care, improving compliance and enabling tighter therapeutic control. At the same time, syndromic surveillance networks deploy multiplex PCR microfluidic chips that differentiate bacterial, viral, and parasitic pathogens in a single run, conserving reagents and shortening isolation decisions for suspected cases. The World Health Organization projects a 34% rise in non-communicable disease load across low- and middle-income regions by 2030, underscoring the urgency for affordable, low-power diagnostic formats. Antimicrobial resistance screening benefits as well; microfluidic susceptibility assays provide drug-response profiles within 6 hours versus 48 hours for culture, supporting stewardship programs that limit empiric antibiotic use. Collectively, these factors propel the microfluidics market toward integrated devices capable of handling diverse sample matrices under minimal infrastructure constraints.

High Capital Cost and Workflow Integration Challenges

Purchasing a droplet digital PCR rig typically demands USD 150,000-250,000 upfront, while fully integrated organ-on-chip stations surpass USD 500,000 once ancillary microscopes, incubators, and service contracts are tallied. Laboratories operating under reimbursement pressure hesitate to commit, especially when payer reviews question incremental clinical benefit. Validation periods last 6-12 months as teams run microfluidic and legacy assays in parallel to satisfy CLIA precision criteria. UnitedHealthcare denied coverage for multiple microfluidic liquid-biopsy tests in 2024, citing insufficient utility evidence, signaling skepticism that slows smaller labs. Shared-service models now emerge: regional reference labs amortize equipment across pooled sample volumes, but adoption still lags in resource-constrained regions, restraining the microfluidics market.

Other drivers and restraints analyzed in the detailed report include:

1. AI-Enabled Lab-on-Chip for Decentralized Molecular Diagnostics
2. Surge in Single-Cell Assays for Immuno-Oncology and Cell-Therapy R&D
3. Regulatory Complexity Across Multi-Jurisdiction Clinical Use

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Microfluidic components accounted for a 55.56% microfluidics market size share in 2025 and are forecast to expand at an 18.25% CAGR to 2031, reflecting end-user preference for building bespoke workflows instead of adopting fixed instruments. Chips, pumps, and valves ordered a-la-carte enable researchers to tailor channel geometries, droplet diameters, and pressure profiles to specific biological assays. High-throughput screening groups favor droplet-generation chips that partition nanoliter reactions, conserving costly reagents. Microneedle arrays grow swiftly inside transdermal vaccine studies, broadening component demand. In parallel, integrated devices continue to secure regulatory clearances for point-of-care diagnostic use, yet their slower update cycle prevents rapid pivot to emerging assays, sustaining component momentum within the microfluidics market.

A second factor is the rise of open-hardware communities publishing photomask files and control scripts under permissive licenses, accelerating academic adoption. Contract manufacturers in South Korea and Taiwan offer short-run PDMS and cyclic-olefin-polymer fabrication at competitive pricing, lowering entry barriers. The component-centric supply chain therefore promotes experimentation in single-cell sequencing, organoid culture, and gradient generation, reinforcing the centrality of components to overall microfluidics market expansion.

Point-of-care diagnostics led 38.53% of 2025 revenue, yet pharmaceutical & biotechnology research is projected to register a 19.85% CAGR, lifting its microfluidics market share as drug discovery groups prioritize reagent savings and assay miniaturization. Droplet microfluidics reduces library screening volumes by up to 1,000-fold, enabling biopharma to test wider compound ranges at constant budget. Contract research organizations, such as Charles River, scaled droplet-based platforms in 2025 to meet sponsor demand, reinforcing commercial traction.

Proteomics advances further amplify research pull: Thermo Fisher's integration of Olink's proximity-extension assay yields 5,000-protein panels processed on microfluidic cartridges, equipping translational studies with multiplexed readouts. In diagnostics, rapid syndromic panels sustain cartridge volumes in emergency and critical-care units, but reimbursement vigilance caps price ceilings. Drug-delivery applications remain exploratory, though microfluidic-fabricated nanoparticles show promise for mRNA and siRNA payloads, implying new medium-term revenue avenues for the microfluidics market.

Complete Report Scope:

• By Product Type
  • Microfluidic-based Devices
  • Microfluidic Components
    • Microfluidic Chips
    • Micro-pumps
    • Microneedles
    • Other Components
• By Application
  • Drug Delivery
  • Point-of-care Diagnostics
  • Pharmaceutical & Biotechnology Research
    • High-throughput Screening
    • Proteomics
    • Genomics
    • Cell-based Assay
    • Capillary Electrophoresis
    • Other Pharma/Biotech Research
  • Clinical Diagnostics
  • Other Applications
• By Material
  • Polymer
  • Silicone
  • Glass
  • Paper & Other Porous Substrates
• By Technology
  • Continuous-flow Microfluidics
  • Digital/Droplet Microfluidics
  • Organ-on-Chip & Tissue-chip
  • Acoustofluidics & Electrowetting
  • Centrifugal & Paper-based Microfluidics
• By End-user
  • Pharmaceutical & Biotechnology Companies
  • Diagnostic Laboratories
  • Academic & Research Institutes
  • Hospitals & Clinics
  • Contract Research & Manufacturing Organisations
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained 34.13% revenue share in 2025, anchored by FDA pathways that expedite clinical testing of microfluidic diagnostics and by Medicare ADLT reimbursement that rewards novel assays demonstrating utility. Venture investment clusters around Boston and the San Francisco Bay Area create rapid iteration loops between startup innovators and pharmaceutical clients. National Institutes of Health programs, such as All of Us, supply millions of biospecimens, ensuring pipeline demand for high-throughput microfluidic preparation kits.

Asia-Pacific is projected to lead growth at a 14.81% CAGR through 2031 as China's 14th Five-Year Plan channels USD 15 billion toward domestic medical-device development, officially naming microfluidics a strategic priority. India's primary-care upgrade programs mandate decentralized diagnostics, perfect for paper-based chips that function without cold chain. Japan's aging society drives home-based monitoring devices, while South Korea's semiconductor prowess lowers chip-fabrication costs. Australia hosts early-stage clinical trials, serving as a launchpad into Southeast Asia.

Europe demonstrates robust academic publication output but slower clinical adoption. The IVDR extension of conformity assessments burdens small manufacturers, extending time to market. Germany's pharma cluster maintains sizeable microfluidic research instrumentation, yet reimbursement uncertainty in France and Italy delays hospital purchases. Post-Brexit divergence adds further complexity for firms targeting both the United Kingdom and EU27. Despite these hurdles, collaborative projects funded under Horizon Europe sustain R&D momentum, preserving relevance of the microfluidics market across the continent.

1. Abcam
2. Agilent Technologies
3. Becton Dickinson & Co.
4. Bio-Rad Laboratories
5. Biosurfit
6. Dolomite Microfluidics (Blacktrace/Unchained Labs)
7. Dropworks Inc.
8. Emulate
9. Fluigent
10. Hesperos
11. Illumina
12. Micronit
13. PerkinElmer
14. QuidelOrtho
15. Sphere Fluidics Ltd.
16. Standard BioTools (Fluidigm)
17. Thermo Fisher Scientific
18. ZEON Corporation

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing demand for point-of-care testing
  • 4.2.2 Rising incidences of chronic and infectious diseases
  • 4.2.3 Rapid turnaround time & device miniaturisation
  • 4.2.4 AI-enabled lab-on-a-chip for decentralised molecular diagnostics
  • 4.2.5 Surge in single-cell assays for immuno-oncology & cell-therapy R&D
• 4.3 Market Restraints
  • 4.3.1 High capital cost & workflow integration challenges
  • 4.3.2 Regulatory complexity across multi-jurisdiction clinical use
  • 4.3.3 Limited reimbursement & low adoption in price-sensitive economies
  • 4.3.4 Supply constraints in medical-grade elastomers & specialty polymers
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Microfluidic-based Devices
  • 5.1.2 Microfluidic Components
    • 5.1.2.1 Microfluidic Chips
    • 5.1.2.2 Micro-pumps
    • 5.1.2.3 Microneedles
    • 5.1.2.4 Other Components
• 5.2 By Application
  • 5.2.1 Drug Delivery
  • 5.2.2 Point-of-care Diagnostics
  • 5.2.3 Pharmaceutical & Biotechnology Research
    • 5.2.3.1 High-throughput Screening
    • 5.2.3.2 Proteomics
    • 5.2.3.3 Genomics
    • 5.2.3.4 Cell-based Assay
    • 5.2.3.5 Capillary Electrophoresis
    • 5.2.3.6 Other Pharma/Biotech Research
  • 5.2.4 Clinical Diagnostics
  • 5.2.5 Other Applications
• 5.3 By Material
  • 5.3.1 Polymer
  • 5.3.2 Silicone
  • 5.3.3 Glass
  • 5.3.4 Paper & Other Porous Substrates
• 5.4 By Technology
  • 5.4.1 Continuous-flow Microfluidics
  • 5.4.2 Digital/Droplet Microfluidics
  • 5.4.3 Organ-on-Chip & Tissue-chip
  • 5.4.4 Acoustofluidics & Electrowetting
  • 5.4.5 Centrifugal & Paper-based Microfluidics
• 5.5 By End-user
  • 5.5.1 Pharmaceutical & Biotechnology Companies
  • 5.5.2 Diagnostic Laboratories
  • 5.5.3 Academic & Research Institutes
  • 5.5.4 Hospitals & Clinics
  • 5.5.5 Contract Research & Manufacturing Organisations
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 Japan
    • 5.6.3.3 India
    • 5.6.3.4 South Korea
    • 5.6.3.5 Australia
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East & Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East & Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Abcam plc
  • 6.3.2 Agilent Technologies Inc.
  • 6.3.3 Becton Dickinson & Co.
  • 6.3.4 Bio-Rad Laboratories Inc.
  • 6.3.5 Biosurfit SA
  • 6.3.6 Dolomite Microfluidics (Blacktrace/Unchained Labs)
  • 6.3.7 Dropworks Inc.
  • 6.3.8 Emulate Inc.
  • 6.3.9 Fluigent SA
  • 6.3.10 Hesperos Inc.
  • 6.3.11 Illumina Inc.
  • 6.3.12 Micronit BV
  • 6.3.13 PerkinElmer Inc.
  • 6.3.14 QuidelOrtho Corporation
  • 6.3.15 Sphere Fluidics Ltd.
  • 6.3.16 Standard BioTools (Fluidigm)
  • 6.3.17 Thermo Fisher Scientific
  • 6.3.18 ZEON Corporation

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment